TOKYO -- Fujifilm Holdings announced on Tuesday that it has signed a contract worth more than $3 billion to manufacture biologic drugs derived from living organisms in the U.S. for a major American pharmaceutical company.
Pharmaceuticals
Japan's Fujifilm rides US-China rift to land $3bn biopharma deal
Policy to expand domestic medicine production will drive rapid growth
Fujifilm's biopharmaceutical plant in Denmark. The Japanese company plans to rapidly expand its U.S. business, and has a new plant opening in North Carolina at the end of the year. (Fujifilm)
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Pharmaceuticals
